Epilepsy in the elderly

Seminars in Neurology

Volumn 22, Issue 3, 2002, Pages 309-319

  Leppik, Ilo E ^a,b   Birnbaum, Angela ^b  

^a MINCEP Epilepsy Care   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Antiepileptic drugs; Elderly; Epilepsy; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; DIAZEPAM; ERYTHROMYCIN; ETIRACETAM; FELBAMATE; FLUOXETINE; FOLIC ACID; GABAPENTIN; KETOCONAZOLE; LAMOTRIGINE; LORAZEPAM; NEUROLEPTIC AGENT; NORFLUOXETINE; OXCARBAZEPINE; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SERTRALINE; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZONISAMIDE;

APLASTIC ANEMIA; COGNITIVE DEFECT; DRUG ABSORPTION; DRUG BINDING; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EPILEPSY; GROUPS BY AGE; HEART ARRHYTHMIA; HEART BLOCK; HEPATITIS; HUMAN; HYPONATREMIA; MEGALOBLASTIC ANEMIA; NEURALGIA; ONSET AGE; PRIORITY JOURNAL; REVIEW; SEDATION;

AGED; ANTICONVULSANTS; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; HUMANS; SEIZURES;

EID: 0036765786     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36650     Document Type: Review

References (69)

1. Hauser WA. Epidemiology of seizures in the elderly. In: Rowan AJ, Ramsay RE, eds. Seizures and Epilepsy in the Elderly. Boston: Butterworth-Heinemann; 1997:7-20
2. Epilepsy Foundation of America. Epilepsy, A Report to the Nation. Landover, MD: Author; 1999
3. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly. Pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994;3:589-598
4. Garrard J, Cloyd JC, Gross C, et al. Factors associated with antiepileptic drug use among nursing home elderly. J Geriatr Med Sci 2000;55:384-392
5. Lackner TE, Cloyd JC, Thomas LW, Leppik KE. Antiepileptic drug use in nursing home residents: Effect of age, gender, and comedication on patterns of use. Epilepsia 1998;39:1083-1087
6. Schachter SS, Cramer GW, Thompson GD, Chaponis RJ, Mendelson MA, Lawhorne L. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998;46:1137-1141
7. Dey AN. Characteristics of elderly home health care users; data from the 1994 National Home and Hospice Care Survey. Adv Data 1996;279:1-12
8. Leppik IE. Contemporary Diagnosis and Management of the Patient with Epilepsy. 5th Ed. Newton, PA: Handbooks in Healthcare; 2001
9. Hauser WA, Hesdorffer DC, eds. Epilepsy, Frequency, Causes and Consequences. New York: Demos Publications; 1990:1-51
10. Moor SA, Teal TW, eds. Adverse drug reaction surveillance in the geriatric population: A preliminary review. Proceedings of the Drug Information Association Workshop Geriatric Drug Use: Clinical and Social Perspectives. Washington, DC: Pergamon Press; 1985
11. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987;12:41-72
12. Greenblatt DJ. Reduced serum albumin concentrations in the elderly: A report from the Boston Collaborative Drug Surveillance Program. J Am Geriatr Soc 1979;27:20-22
13. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: A cross-sectional and longitudinal study. J Gerontol 1976;31:155-163
14. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984;27:91-97
15. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age on liver volume and apparent liver blood flow in healthy man. Hepatology 1989;9:297-301
16. Tiuta E, Neuvonen PJ. Antiepileptic drugs and alpha-1 acid glycoprotein. N Engl J Med 1982;307:1148
17. Cusack BJ. Drug metabolism in the elderly. J Clin Pharmacol 1988;28:571-576
18. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly: An update. Clin Pharmacokinet 1989;17:236-263
19. Woodhouse KW, Wynne HA. Hepatic drug metabolism and aging. Br Med Bull 1988;15:287-296
20. Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: Influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975;18:425-432
21. Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp Ther 1980;215:86-91
22. Faich GA, Dreis M, Tomita D. National adverse drug reaction surveillance 1986. Arch Intern Med 1988;148:785-787
23. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151
24. Bauer LA, Blouin RA. Age and phenytoin kinetics in adult epileptics. Clin Pharmacol Ther 1982;31:301-304
25. Bach B, Hansen JM, Kampmann JP, Rasmussen SN, Skovsted L. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981;6:389-396
26. Hayes MJ, Langman MJS, Short AH. Changes in drug metabolism with increasing age: II. Phenytoin clearance and protein binding. Br J Clin Pharmacol 1975;2:73-79
27. Houghton GW, Richens A, Leighton M. Effects of age, height, weight and sex on serum phenytoin concentrations in epileptic patients. Br J Clin Pharmacol 1975;2:251-256
28. Lambie DC, Caird FL. Phenytoin dosage in the elderly. Age Ageing 1977;6:133-137
29. Troupin AS, Johannessen SI. Epilepsy in the elderly: A pharmacologic perspective. In: Smith DB, ed. Epilepsy: Current Approaches to Diagnosis and Treatment. New York: Raven Press; 1990:141-153
30. Mooradian AD, Hernandez L, Tamai IC, Marshall C. Variability of serum phenytoin concentrations in nursing home patients. Arch Intern Med 1989;149:890-892
31. Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 2001;44:71-82
32. Bohannon AD, Hanlon JT, Landerman R, Gold DT. Association of race and other potential risk factors with nonvertebral fractures in community-dwelling elderly women. Am J Epidemiol 1999;149:1002-1009
33. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: Unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985;37:697-700
34. Bryson SM, Verma N, Scott PJYV, et al. Pharmacokinetics of valproic acid in young and elderly subjects. Br J Clin Pharmacol 1983;16:104-105
35. Perucca E, Grimaldi R, Gatti G, Pirracchio S, Crema F, Frigo GM. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-669
36. Graves NM. Felbamate. Ann Pharmacother 1993;27:1073-1081
37. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New Trends in Epilepsy Management: The Role of Gabapentin. London: Royal Society of Medicine Services; 1993:41-46
38. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991;32(suppl 2):S9-S12
39. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-128
40. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997;43:457-465.
41. Yuen AW, Land G, Weatherley BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-513
42. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-780
43. Levy RH, Bishop F, Streeter AJ, et al. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibition spectrum. In: Cereghino J, ed. Annual Meeting of the American Epilepsy Society. Baltimore: Lippincott-Raven; 1995:47
44. Faigle JW, Menge GP. Metabolic characteristics of oxcarbazepine (Trileptal) and their beneficial implications for enzyme induction and drug interactions. Behav Neurol 1990;3:21-30
45. van Heiningen PN, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991;50:410-419
46. Klosterskov JP, Saano V, Harin P, Svenstrup B, Nenge G. Possible interaction between oxcarbazepine and an oral contraceptive. Epilepsia 1992;33:1149-1152
47. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit 1993;15:39-42
48. Hossain M, Sallas W, Gasparini M, et al. Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 1999;52(suppl 2):A525(abstract)
49. Isojarvi JIT, Huuskonen UEJ, Pakarinen AJ, Vuolteenaho O, Myllyla VV. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001;42:741-745
50. Leppik IE. The place of levetiracetam in the treatment of epilepsy. Epilepsia 2001;42:44-45
51. Patsalos PN, Sander JW. Newer antiepileptic drugs. Towards an improved risk-benefit ratio. Drug Saf 1994;11:37-67
52. French J. Use of levetiracetam in special populations. Epilepsia 2001;42:40-43
53. Cook PJ, Flanagan R, James IM. Diazepam tolerance: Effect of age, regular sedation and alcohol. Br Med J 1984;289:351-353
54. Hansten PD, Horn JR, eds. Drug Interactions: A Clinical Perspective and Analysis of Current Developments. Vancouver, WA: Applied Therapeutics Inc; 1993:331-371
55. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin, I, II. Clin Pharmacokinet 1990;18:37-60, 131-150
56. Bollini P, Riva R, Albani F, et al. Decreased phenytoin levels during antineoplastic therapy: A case report. Epilepsia 1983;24:75-78
57. Neef C, de Voogd-van den Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 1988;43:372-375
58. Haley CJ, Nelson J. Phenytoin-enteral feeding interaction. Ann Pharmacother 1989;23:796-798
59. Sandor P, Sellers EM, Dumbrell M, Khouse V. Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics. Clin Pharmacol Ther 1981;30:390-397
60. Cold JA, Wells BG, Froemming JH. Seizure activity associated with antipsychotic therapy. Ann Pharmacother 1990;24:601-606
61. Bender AD, Post A, Meier JP, Higson JE, Reichard G Jr. Plasma protein binding of drugs as a function of age in adult human subjects. J Pharm Sci 1975;64:1711-1713
62. Drinka PJ, Miller J, Voeks SK, Hamel P. Phenytoin binding in a nursing home. J Geriatr Drug Ther 1988;3:73-82
63. Eadie MJ, Lander CM, Hooper WD, Tyrer JH. Factors influencing plasma phenobarbital levels in epileptic patients. Br J Clin Pharmacol 1977;4:41-47
64. Edwards GB, Culberton VL, Anresen GB, Rhodes PJ. Free phenytoin concentrations in geriatrics. J Geriatr Drug Ther 1988;3:97-102
65. Martines C, Gatti G, Sasso E, Calzetti S, Perucca E. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990;30:607-611
66. Morselli PL, ed. Carbamazepine: Absorption, Distribution and Excretion. Antiepileptic Drugs. 3rd Ed. New York: Raven Press; 1989:473-490
67. Patterson M, Heazelwood R, Smithhurst B, Eadie MJ. Plasma protein binding of phenytoin in the aged: In-vivo studies. Br J Clin Pharmacol 1982;13:423-425
68. Sherwin AL, Loynd JS, Bock GW, Sokolowski CD. Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels. Epilepsia 1974;15:507-521
69. Umstead GS, Morales M, McKercher PI. Comparison of total, free, and salivary phenytoin concentrations in geriatric patients. Clin Pharm 1986;5:59-62